Company Overview and News

 
Sundance Energy Australia Limited Reports First Quarter 2018 Financial and Operational Results

2018-05-16 globenewswire
DENVER, May 16, 2018 (GLOBE NEWSWIRE) -- Sundance Energy Australia Limited (ASX:SEA) (NASDAQ:SNDE) (“Sundance” or the “Company”), a U.S. onshore oil and gas exploration and production company focused in the Eagle Ford in South Texas, reported its first quarter 2018 financial and operations results.

 
A seismic exchange of strategy

2018-05-16 nzherald.co.nz
Last year there was just one initial public offering on the New Zealand Stock Exchange's main board versus eight de-listings — despite the local sharemarket having otherwise enjoyed a record-breaking 12 months.

 
[email protected]: ASX poised to edge higher at the open

2018-05-13 theage.com.au
Wall Street edged higher on Friday and the ASX is set up to open the week in a similar vein.

 
[email protected]: ASX poised to edge higher at the open

2018-05-13 smh.com.au
Wall Street edged higher on Friday and the ASX is set up to open the week in a similar vein.

 
Wages growth anchored near all time lows despite booming jobs growth

2018-05-13 abc.net.au
The recent release of enterprise bargaining agreements (EBAs) from the final quarter of 2017 certainly showed promise.

 
Decade-high hopes for market

2018-05-11 ntnews.com.au
The latest government figures show Australia has just days of emergency stocks of fuel in reserve amid widespread turmoil in the region and the Middle East. Fairfax Media is reporting the country has only a 22-day supply of crude oil, 59 days of LPG, 20 days of petrol, 19 days of aviation fuel and 21 days of diesel. The International Energy Agency expects countries to keep a 90-day supply, but Australia has under 50 days.

 
Bourse on longest run up in two years despite weekly peaks and troughs

2018-05-11 perthnow.com.au
THE Australian share market has notched up its longest winning streak in two years as it eyes off a new decade high.

 
Markets Live: ASX close to 10 year highs

2018-05-11 theage.com.au
The S&P/ASX 200 index finished up 10.7 points at 6,118.7, a gain of 0.2 per cent, helped on by energy stocks as the index fell just shy of a decade long high.

 
Markets are surging but we can't claim much credit

2018-05-11 theage.com.au
Something curious started happening about three weeks ago. The Australian dollar suddenly began a steep slide and the Australian sharemarket a sharp upturn.

 
ASX edges towards 10-year high

2018-05-11 theage.com.au
The ASX gained on Thursday to within 5 points of the highest intra-day level in 10 years.

 
Markets Live: ASX close to 10 year highs

2018-05-11 smh.com.au
The S&P/ASX 200 index finished up 10.7 points at 6,118.7, a gain of 0.2 per cent, helped on by energy stocks as the index fell just shy of a decade long high.

 
Markets are surging but we can't claim much credit

2018-05-11 smh.com.au
Something curious started happening about three weeks ago. The Australian dollar suddenly began a steep slide and the Australian sharemarket a sharp upturn.

 
ASX edges towards 10-year high

2018-05-11 smh.com.au
The ASX gained on Thursday to within 5 points of the highest intra-day level in 10 years.

 
R Kelly’s music banned

2018-05-10 ntnews.com.au
The ASX 200 has finished firmer for the ninth time in the past 10 sessions today. The index was boosted by a rally in the energy sector following a surge in oil prices overnight to 3.5 year highs.

 
Buffett not worried about China

2018-05-06 ntnews.com.au
The ASX 200 has climbed 1.85% over the week, recording its best weekly performance in 14 months. The index did decline on Friday though, slipping 0.6%.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: AA6129222